Resources on COVID-19 and how BCBSND is responding to help protect all North Dakotans

Copanlisib (Aliqopa)

Section: Injections
Effective Date: December 01, 2019
Revised Date: November 26, 2019


Copanlisib (AliqopaTM) is a kinase inhibitor indicated for the treatment of adults with relapsed follicular lymphoma (FL) who have received at least two previous systemic therapies. It is an inhibitor of phosphatidylinositol-3-kinase (PI3K) against the two main forms of PI3K expressed in malignant B cells. It induces tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines. It also inhibits several key cell-signaling pathways, including B-cell receptor (BCR) signaling, Chemokine Receptor 12 (CXCR12) mediated chemotaxis of malignant B cells and NFkB signaling in lymphoma cell lines.


Coverage is subject to the specific terms of the member’s benefit plan.

Federal Employee Program members (FEP) should check with their Retail Pharmacy Program to determine if prior approval is required by calling the Retail Pharmacy Program at 1-800-624-5060 (TTY: 1-800-624-5077). FEP members can also obtain the list through the website.

Copanlisib (Aliqopa) may be considered medically necessary in adults for the following indications:

Food and Drug Administration (FDA) Indications

For the treatment of individuals with relapsed follicular lymphoma (FL) who have received at least two (2) prior systemic therapies; or

National Comprehensive Cancer Network (NCCN) Indications

For ANY of the following indications after two (2) prior therapies:

  • As a subsequent therapy for relapsed/refractory disease for ANY of the following:
    • Follicular lymphoma (grade 1-2); or
    • Gastric mucosa associated lymphoid tissue (MALT) lymphoma; or
    • Non-gastric MALT lymphoma ; or
    • Nodal marginal zone lymphoma; or
    • Splenic marginal zone lymphoma; or
  • As a second-line therapy for relapsed/refractory follicular lymphoma (grade 1-2).

The use of copanlisib (Aliqopa) for any other indication will be considered experimental/investigational and therefore non-covered as published peer reviewed literature does not support its efficacy or safety for any other indication.

Procedure Codes


NOTE: In addition to the above criteria, product specific dosage and/or frequency limits may apply in accordance with the U.S. Food and Drug Administration (FDA)-approved product prescribing information, national compendia, Centers for Medicare and Medicaid Services (CMS) and other peer reviewed resources or evidence-based guidelines. Blue Cross Blue Shield of North Dakota may deny, in full or in part, reimbursement for utilization that does not fall within the applicable dosage and/or frequency limits.

Diagnosis Codes

Covered Diagnosis Codes

C82.00 C82.01 C82.02 C82.03 C82.04 C82.05 C82.06
C82.07 C82.08 C82.09 C82.10 C82.11 C82.12 C82.13
C82.14 C82.15 C82.16 C82.17 C82.18 C82.19 C82.20
C82.21 C82.22 C82.23 C82.24 C82.25 C82.26 C82.27
C82.28 C82.29 C82.30 C82.31 C82.32 C82.33 C82.34
C82.35 C82.36 C82.37 C82.38 C82.39 C82.40 C82.41
C82.42 C82.43 C82.44 C82.45 C82.46 C82.47 C82.48
C82.49 C82.50 C82.51 C82.52 C82.53 C82.54 C82.55
C82.56 C82.57 C82.58 C82.59 C82.60 C82.61 C82.62
C82.63 C82.64 C82.65 C82.66 C82.67 C82.68 C82.69
C82.80 C82.81 C82.82 C82.83 C82.84 C82.85 C82.86
C82.87 C82.88 C82.89 C82.90 C82.91 C82.92 C82.93
C82.94 C82.95 C82.96 C82.97 C82.98 C82.99 C83.00
C83.01 C83.02 C83.03 C83.04 C83.05 C83.06 C83.07
C83.08 C83.09 C83.80 C83.81 C83.82 C83.83 C83.84
C83.85 C83.86 C83.87 C83.88 C83.89 C85.80 C85.81
C85.82 C85.83 C85.84 C85.85 C85.86 C85.87 C85.88
C85.89 C88.4